MCID: NNS003
MIFTS: 34

Non-Secretory Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Non-Secretory Myeloma

MalaCards integrated aliases for Non-Secretory Myeloma:

Name: Non-Secretory Myeloma 12 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9547
UMLS 74 C0456845

Summaries for Non-Secretory Myeloma

MalaCards based summary : Non-Secretory Myeloma is related to myeloma, multiple and indolent myeloma. An important gene associated with Non-Secretory Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and ECM-receptor interaction. The drugs Lenalidomide and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include b cells, kidney and skin, and related phenotypes are Decreased shRNA abundance and Decreased shRNA abundance

Related Diseases for Non-Secretory Myeloma

Diseases related to Non-Secretory Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 29.4 ALB B2M CD19 CD38 MYOM2 NCAM1
2 indolent myeloma 10.4 B2M MYOM2
3 extramedullary plasmacytoma 10.4 B2M MYOM2
4 amyloid tumor 10.3 B2M MYOM2
5 immunodeficiency 43 10.3 ALB B2M
6 orthostatic proteinuria 10.3 ALB B2M
7 diffuse glomerulonephritis 10.3 ALB B2M
8 danubian endemic familial nephropathy 10.3 ALB B2M
9 invasive malignant thymoma 10.2 CD19 CD38
10 commensal bacterial infectious disease 10.2 MYOM2 SETBP1
11 glomeruloid hemangioma 10.2 CD68 MYOM2
12 al amyloidosis 10.2 B2M VWF
13 acute kidney tubular necrosis 10.2 ALB B2M
14 b cell prolymphocytic leukemia 10.2 CD19 CD38
15 gamma heavy chain disease 10.2 CD19 CD38
16 osteosclerotic myeloma 10.2 MYOM2 VWF
17 selective igg deficiency disease 10.2 CD19 NCAM1
18 small intestine lymphoma 10.1 B2M CD19 ITGAE
19 acquired immunodeficiency syndrome 10.1 ALB B2M CD38
20 plasma protein metabolism disease 10.1 CD19 CD38 MYOM2
21 meningoencephalitis 10.1 ALB B2M
22 parasitic ichthyosporea infectious disease 10.1 CD68 NCAM1
23 rhinosporidiosis 10.1 CD68 NCAM1
24 ulcerative stomatitis 10.1 ALB CD68
25 granulomatous myositis 10.1 CD68 NCAM1
26 hemorrhagic fever with renal syndrome 10.1 ALB B2M
27 lung lymphoma 10.1 CD19 NCAM1
28 hepatic vascular disease 10.1 ALB VWF
29 lymphatic system cancer 10.1 CD19 NCAM1
30 aleukemic leukemia cutis 10.1 CD68 NCAM1
31 anterior scleritis 10.0 B2M CD19 NCAM1
32 b-cell expansion with nfkb and t-cell anergy 10.0 B2M CD38
33 myxosarcoma 10.0 CD68 VWF
34 uremia 10.0 ALB B2M VWF
35 pleuropneumonia 10.0 CD19 CXCL9
36 endocervicitis 10.0 CD68 CXCL9
37 hepatopulmonary syndrome 10.0 ALB VWF
38 waldenstroem's macroglobulinemia 10.0 B2M CD19 CD38 MYOM2
39 bladder lymphoma 9.9 CD19 ITGAX
40 myelodysplastic syndrome 9.9
41 disseminated intravascular coagulation 9.9
42 relapsing polychondritis 9.9
43 kidney disease 9.9
44 amyloidosis 9.9
45 polymyositis 9.9
46 plica syndrome 9.9 CD38 CD68 VWF
47 pericoronitis 9.9 CD19 CD68 NCAM1
48 rhinoscleroma 9.9 CD19 CD68 NCAM1
49 bone marrow cancer 9.9 B2M CD38 MYOM2 VWF
50 hematologic cancer 9.8 CD19 CD38 NCAM1

Graphical network of the top 20 diseases related to Non-Secretory Myeloma:



Diseases related to Non-Secretory Myeloma

Symptoms & Phenotypes for Non-Secretory Myeloma

GenomeRNAi Phenotypes related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance GR00251-A-1 9.7 B2M CD19 DDX53 NCAM1 SETBP1 VWF
2 Decreased shRNA abundance GR00251-A-2 9.7 B2M CD19 DDX53 NCAM1 SETBP1 VWF

Drugs & Therapeutics for Non-Secretory Myeloma

Drugs for Non-Secretory Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 3 191732-72-6 216326
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
3
Pomalidomide Approved Phase 3,Phase 2 19171-19-8
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
5
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
6 interferons Phase 3
7
protease inhibitors Phase 3,Phase 2,Phase 1
8 Angiogenesis Modulating Agents Phase 3,Phase 2
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
10 Immunologic Factors Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 3,Phase 2
12 Hormones Phase 3,Phase 2
13 Anti-Bacterial Agents Phase 3,Phase 2
14 Autonomic Agents Phase 3,Phase 2
15 Antiemetics Phase 3,Phase 2
16 Anti-Infective Agents Phase 3,Phase 2
17 glucocorticoids Phase 3,Phase 2
18 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Hormonal Phase 3,Phase 2
20 Gastrointestinal Agents Phase 3,Phase 2
21 BB 1101 Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 3,Phase 2
24 Angiogenesis Inhibitors Phase 3,Phase 2
25 Hormone Antagonists Phase 3,Phase 2
26
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
27
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Histone Deacetylase Inhibitors Phase 2
34 Antineoplastic Agents, Alkylating Phase 2
35 Antirheumatic Agents Phase 2
36 Alkylating Agents Phase 2
37 Vaccines Phase 2
38 Neuroprotective Agents Phase 2
39 Bendamustine Hydrochloride Phase 2
40 Prednisolone acetate Phase 2
41 Methylprednisolone Acetate Phase 2
42 Protective Agents Phase 2
43
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
44
Ixazomib Approved, Investigational Phase 1 1072833-77-2
45
Sodium Citrate Approved, Investigational Phase 1 68-04-2
46
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
47
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1 77-92-9 311
49 Protein Kinase Inhibitors Phase 1
50 Proteasome Inhibitors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) Completed NCT00732641 Phase 3 Peginterferon
2 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Completed NCT01311687 Phase 3 pomalidomide;Dexamethasone
3 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
4 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 2 panobinostat;bortezomib;dexamethasone
5 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma Completed NCT02011113 Phase 2 Pomalidomide;Dexamethasone
6 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
7 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Completed NCT01849848 Phase 2 SyB L-0501
8 Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma Terminated NCT01179490 Phase 2 SyB L-0501;prednisolone
9 Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Completed NCT00303797 Phase 1 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;sorafenib tosylate
10 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed NCT00963820 Phase 1 Ixazomib citrate

Search NIH Clinical Center for Non-Secretory Myeloma

Genetic Tests for Non-Secretory Myeloma

Anatomical Context for Non-Secretory Myeloma

MalaCards organs/tissues related to Non-Secretory Myeloma:

42
B Cells, Kidney, Skin, Bone, Bone Marrow, Myeloid, Small Intestine

Publications for Non-Secretory Myeloma

Articles related to Non-Secretory Myeloma:

(show all 18)
# Title Authors Year
1
Non-Secretory Myeloma: Ready for a new Definition? ( 28894562 )
2017
2
Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. ( 27504298 )
2016
3
A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. ( 26003102 )
2015
4
Non-secretory myeloma: a clinician's guide. ( 24282993 )
2013
5
Non-secretory myeloma: one, two, or more entities? ( 24282994 )
2013
6
Non-secretory myeloma: clinical and biologic implications. ( 24282995 )
2013
7
Polymyositis associated with non-secretory myeloma - a case report. ( 23393512 )
2011
8
Non-secretory myeloma: a rare variant of multiple myeloma. ( 18803898 )
2008
9
Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. ( 10634653 )
2000
10
Twelve-year profile of a non-secretory myeloma with amyloidosis. ( 2282322 )
1990
11
Hypercalcaemia in a patient with non-secretory myeloma. ( 3211820 )
1988
12
Skin involvement in non-secretory myeloma. ( 3407670 )
1988
13
Hypercalcaemia in "non-secretory" myeloma. ( 3546006 )
1986
14
Non-secretory myeloma. ( 3793705 )
1986
15
Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing. ( 3926829 )
1985
16
Disseminated intravascular coagulation in a case of non-secretory myeloma. ( 6511287 )
1984
17
Ultrastructural features of the plasma cells in "non-secretory" myeloma. ( 346091 )
1978
18
Intact and fragmented intracellular immunoglobulin in a case of non-secretory myeloma. ( 1123437 )
1975

Variations for Non-Secretory Myeloma

Expression for Non-Secretory Myeloma

Search GEO for disease gene expression data for Non-Secretory Myeloma.

Pathways for Non-Secretory Myeloma

GO Terms for Non-Secretory Myeloma

Cellular components related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 B2M CD38 ITGAX NCAM1
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CXCL9 ITGAE ITGAX NCAM1
3 integrin complex GO:0008305 8.96 ITGAE ITGAX

Biological processes related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.56 ITGAE ITGAX NCAM1 VWF
2 retina homeostasis GO:0001895 9.16 ALB B2M
3 extracellular matrix organization GO:0030198 9.13 ITGAE ITGAX VWF
4 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 8.62 CD19 CXCL9

Sources for Non-Secretory Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....